373 related articles for article (PubMed ID: 32329881)
1. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.
Diurno F; Numis FG; Porta G; Cirillo F; Maddaluno S; Ragozzino A; De Negri P; Di Gennaro C; Pagano A; Allegorico E; Bressy L; Bosso G; Ferrara A; Serra C; Montisci A; D'Amico M; Schiano Lo Morello S; Di Costanzo G; Tucci AG; Marchetti P; Di Vincenzo U; Sorrentino I; Casciotta A; Fusco M; Buonerba C; Berretta M; Ceccarelli M; Nunnari G; Diessa Y; Cicala S; Facchini G
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):4040-4047. PubMed ID: 32329881
[TBL] [Abstract][Full Text] [Related]
2. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
[TBL] [Abstract][Full Text] [Related]
4. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
6. Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Massabeti R; Cipriani MS; Valenti I
J Popul Ther Clin Pharmacol; 2020 Jul; 27(S Pt 1):e26-e30. PubMed ID: 32650356
[TBL] [Abstract][Full Text] [Related]
7. Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19 in a New York Hospital and Predictors of ICU Care and Ventilation.
Singer AJ; Morley EJ; Meyers K; Fernandes R; Rowe AL; Viccellio P; Thode HC; Bracey A; Henry MC
Ann Emerg Med; 2020 Oct; 76(4):394-404. PubMed ID: 32563601
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.
Hong KS; Lee KH; Chung JH; Shin KC; Choi EY; Jin HJ; Jang JG; Lee W; Ahn JH
Yonsei Med J; 2020 May; 61(5):431-437. PubMed ID: 32390367
[TBL] [Abstract][Full Text] [Related]
9. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
10. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
11. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria.
Akyala AI; Iwu CJ
Pan Afr Med J; 2020; 37():47. PubMed ID: 33209174
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia.
Tian J; Xu Q; Liu S; Mao L; Wang M; Hou X
Curr Med Res Opin; 2020 Nov; 36(11):1747-1752. PubMed ID: 32986475
[TBL] [Abstract][Full Text] [Related]
14. [The first wave of COVID-19 in Intensive care].
Marchetta S; Lambermont B; Massion P; Rousseau AF; Layios N; Robinet S; Canivet JL; Kisoka G; Ledoux D; Morimont P; Piret S; Wiesen P; Misset B
Rev Med Liege; 2020 Sup; 75(S1):18-28. PubMed ID: 33211418
[TBL] [Abstract][Full Text] [Related]
15. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
Fragoso-Saavedra S; Iruegas-Nunez DA; Quintero-Villegas A; García-González HB; Nuñez I; Carbajal-Morelos SL; Audelo-Cruz BM; Arias-Martínez S; Caro-Vega Y; Calva JJ; Luqueño-Martínez V; González-Duarte A; Crabtree-Ramírez B; Crispín JC; Sierra-Madero J; Belaunzarán-Zamudio PF; Valdés-Ferrer SI
BMC Infect Dis; 2020 Oct; 20(1):765. PubMed ID: 33066761
[TBL] [Abstract][Full Text] [Related]
16. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.
Lai CC; Shih TP; Ko WC; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2020 Mar; 55(3):105924. PubMed ID: 32081636
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].
Zhang T; Sun LX; Feng RE
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jun; 43(6):496-502. PubMed ID: 32241072
[TBL] [Abstract][Full Text] [Related]
18. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
[TBL] [Abstract][Full Text] [Related]
19. Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series.
Burwick RM; Dellapiana G; Newman RA; Smithson SD; Naqvi M; Williams J; Wong MS; Bautista M; Gaden A; Kazani SD; Dunn DA; Ma MH; Mitter S; Monteleone JPR; Ortiz SR; Ghandehari S; Merin N; Zakowski MI; Karumanchi SA
Am J Reprod Immunol; 2022 Aug; 88(2):e13559. PubMed ID: 35514201
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.
Annane D; Heming N; Grimaldi-Bensouda L; Frémeaux-Bacchi V; Vigan M; Roux AL; Marchal A; Michelon H; Rottman M; Moine P;
EClinicalMedicine; 2020 Nov; 28():100590. PubMed ID: 33173853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
